Back

Outcomes and predictors of mortality in patients with acute leukemia undergoing percutaneous coronary intervention (PCI) : a 7-year U.S analysis

19 June 2026 (11:45 - 12:45)
Organised by: Logo
Congress Presentation Part of: Coronary syndromes and thromboembolic complications in patients with cancer Diagnosis and Management of Cardiovascular Disease in Patients with Cancer Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Mr Adam Bolad

Zionsville (United States of America)

6 More presentations in this session

Presentation thumbnail
High-risk coronary plaque on coronary ct angiography predicts short-term cardiovascular events in cancer survivors with predominantly non-obstructive disease
Doctor T. De Silva (Kings Lynn, GB)
Abstract Slides
Presentation thumbnail
The role of coronary angiography-derived index of microcirculatory resistance in evaluating coronary microcirculatory function and prognosis in cancer patients
Doctor W. Zhang (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Active malignancy modifies the association between temporary mechanical circulatory support and in-hospital mortality in high-risk percutaneous coronary intervention
Doctor S. Govindji (Saint Louis, US)
Abstract Slides
Presentation thumbnail
Incidence and management of venous thromboembolism in patients with glioblastoma: a retrospective single-center analysis
Mr F. Bordon Orsingher (Cdad. Autonoma De Buenos Aires, AR)
Abstract Slides
Presentation thumbnail
Comparison of direct oral anticoagulants and low-molecular-weight heparins in cancer patients with nonvalvular atrial fibrillation: insights from a single-center experience
Doctor I. Ceren (Ankara, TR)
Abstract Slides

Access the full session

Session thumbnail
Coronary syndromes and thromboembolic complications in patients with cancer

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 11:45 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources